SLC2A1 and neoplasm: GLUT inhibitors ritonavir and indinivar, reduce glucose intake and GBM cell viability, while ManWZB117, another GLUT1 inhibitor, is effective in hampering GSCs proliferation, but not in inhibiting tumor progression (Figure 5B) (Shibuya et al., 2015; Azzalin et al., 2017; Garcia et al., 2021).